SCHEMBL18705378

SCHEMBL18705378

NCc1ccccc1C(=O)NCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 6/20 0.58
▸ CA1 P00915 6/20 0.58
▸ CA2 P00918 6/20 0.58
▸ CA9 Q16790 6/20 0.58
▸ TDP1 Q9NUW8 5/20 0.58
▸ HPSE Q9Y251 1/20 0.56
▸ FOLH1 Q04609 1/20 0.52
▸ PKM P14618 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ ABL1 P00519 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ IDE P14735 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ RIN1 Q13671 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ ITGB1 P05556 1/20 0.50
▸ ITGA4 P13612 1/20 0.50
▸ SLC6A4 P31645 1/20 0.49
▸ F2 P00734 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9412852 0.83 TDP1 (0.74) CA12CA1CA2CA9TDP1
SCHEMBL30737245 0.83 CA12 (0.57) CA12CA1CA2CA9TDP1
SCHEMBL18736485 0.82 CA12 (0.59) CA12CA1CA2CA9TDP1
SCHEMBL30737307 0.82 CA12 (0.56) CA12CA1CA2CA9TDP1
Biotin SCHEMBL31578485 0.82 TDP1 (0.68) CA12CA1CA2CA9TDP1
Hydrochloric Acid SCHEMBL20520179 0.81 CA12 (0.58) CA12CA1CA2CA9TDP1
SCHEMBL25014977 0.81 TDP1 (0.72) CA12CA1CA2CA9TDP1
SCHEMBL15895090 0.81 TDP1 (0.72) CA12CA1CA2CA9TDP1
SCHEMBL10000338 0.81 TDP1 (0.72) CA12CA1CA2CA9TDP1
SCHEMBL24420141 0.81 TDP1 (0.72) CA12CA1CA2CA9TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF Centauri Therapeutics Limited (GB/GB) (GB) 2021-12-02 — — US disclosed
US-10953100-B2 Compounds and therapeutic uses thereof CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2021-03-23 — — US disclosed
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) 2018-10-04 — — US disclosed
WO-2017060729-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CENTAURI THERAPEUTICS LIMITED (GB) 2017-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210369850-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 CA12 2887/4885CA1 4372/4885CA2 4521/4885
US-10953100-B2 Compounds and therapeutic uses thereof CD47, MYD88, NFATC1 CA12 2887/4885CA1 4372/4885CA2 4521/4885
US-20180280521-A1 COMPOUNDS AND THERAPEUTIC USES THEREOF CD47, MYD88, NFATC1 CA12 2887/4885CA1 4372/4885CA2 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback